Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status

European Journal of Cancer

Volumn 40, Issue 18, 2004, Pages 2742-2747

  Dixon, J M ^a   Jackson, J ^a   Hills, M ^b   Renshaw, L ^a   Cameron, D A ^a   Anderson, T J ^a   Miller, W R ^a   Dowsett, M ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Anastrozole; Breast tumours; Endocrine; erbB2; Oestrogen; Postmenopausal

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST TUMOR; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE OVEREXPRESSION; HUMAN; MEASUREMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; ULTRASOUND;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL PROLIFERATION; DOUBLE-BLIND METHOD; FEMALE; GENES, ERBB-2; HUMANS; LYMPHATIC METASTASIS; NITRILES; POSTMENOPAUSE; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; TRIAZOLES;

EID: 9644262523     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.08.025     Document Type: Article

References (24)

1. D.J. Slamon, W. Godolphin, and L.A. Jones Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
2. D.J. Slamon, G. Clark, and S.G. Wong Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene Science 235 1987 177 182
3. H. Yamauchi, A. O'Neill, and R. Gelman Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein J Clin Oncol 15 1997 2518 2525
4. A. Bianco, M. De Laurentiis, and C. Carlomagno HER2 overexpression predicts adjuvant tamoxifen (TAM) failure of early breast cancer (EBC): complete data at 20 yrs of the Naples GUN randomized trial Proc ASCO 19 2000 75a Abstract 289
5. M. De Laurentiis, G. Arpino, and E. Massereli A meta-analysis of the interaction between HER2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC) Proc ASCO 19 2000 78a Abstract 300
6. R.K. Gregory, T.J. Powles, and J. Salter Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy Breast Cancer Res Treat 59 2000 171 175
7. M. Dowsett, C. Harper-Wynne, and I. Boeddinghaus HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer Cancer Res 61 2001 8452 8458
8. A. Lipton, S.M. Ali, and K. Leitzel Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer J Clin Oncol 20 2002 1467 1472
9. B.A. Gusterson, R.D. Gelber, and A. Goldhirsch Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group J Clin Oncol 10 1992 1049 1056
10. D.W. Miles, W.H. Harris, and C.E. Gillett Effect of c-erbB (2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil Int J Cancer 84 1999 354 359
11. M.J. Ellis, A. Coop, and B. Singh Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB1 and/or ErbB2-positive, estrogen receptor positive primary breast cancer: evidence from a Phase III randomized trial J Clin Oncol 19 2001 3808 3816
12. C. Wright, B. Angus, and S. Nicholson Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer Cancer Res 49 1989 2087 2090
13. A. Borg, B. Baldetorp, and M. Ferno ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer Cancer Lett 81 1994 137 144
14. C. Carlomagno, F. Perrone, and C. Gallo c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases J Clin Oncol 14 1996 2701 2708
15. S.J. Houston, T.A. Plunket, and D.M. Barnes Overexpression of c-erbB-2 is an independent marker of resistance to endocrine therapy in advanced breast cancer Br J Cancer 79 1999 1220 1226
16. R.M. Elledge, S. Green, and D. Ciocca HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer. A southwest oncology group study Clin Cancer Res 4 1998 7 12
17. J.M. Nabholtz, A. Buzdar, and M. Pollak Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women - results of a North American multicenter randomized trial J Clin Oncol 18 2000 3758 3776
18. J. Bonneterre, A. Buzdar, and J.M.A. Nabholtz Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma. Results of two randomized trials designed for combined analysis Cancer 92 2001 2247 2258
19. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 2002, 359, 2131-39
20. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in combination) trial efficacy and safety update analyses. Cancer, 2003, 98, 1802-10
21. A. Milla-Santos, L. Milla, and N. Calvo Anastrozole is an effective neoadjuvant therapy for patients with hormone-dependent, locally-advanced breast cancer irrespective of cerbB2 Proc ASCO 22 2003 39 Abstract 154
22. J.M. Dixon, L. Renshaw, and C. Bellamy The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study Clin Cancer Res 6 2000 2229 2235
23. C.C. Benz, G.K. Scott, and J.C. Sarup Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu Breast Cancer Res Treat 24 1993 85 95
24. H. Lee, F. Jiang, and Q. Wang MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells Mol Endocrinol 14 2000 1882 1896